04693116001
Roche
cOmplete™ Protease Inhibitor Cocktail
Tablets provided in EASYpacks
Sinónimos:
protease inhibitor
Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
About This Item
Código UNSPSC:
12352204
NACRES:
NA.21
Productos recomendados
formulario
tablet
envase
pkg of 20 tablets
fabricante / nombre comercial
Roche
solubilidad
water: soluble
absorción
0.08 at 280 nm
temp. de almacenamiento
2-8°C
Descripción general
cOmplete Protease Inhibitor Tablets inhibit a broad spectrum of serine, cysteine, and metalloproteases, as well as calpains. Due to the optimized composition of the tablets, they show excellent inhibition effects, and are well suited for the protection of proteins isolated from animal tissues, plants, yeast, and bacteria.
cOmplete tablets contain EDTA and both irreversible and reversible protease inhibitors. Protease inhibitors present in cOmplete Tablets do not form irreversible complexes with the SH groups of proteins.
cOmplete tablets contain EDTA and both irreversible and reversible protease inhibitors. Protease inhibitors present in cOmplete Tablets do not form irreversible complexes with the SH groups of proteins.
Especificidad
Inhibits a broad spectrum of serine proteases, cysteine proteases, and metalloproteases, as well as calpains.
Aplicación
cOmplete™ Protease Inhibitor Cocktail has been used as an component in
- extraction buffer for protein extraction from Arabidopsis seedling
- in radioimmunoprecipitation assay (RIPA) buffer for the isolation of protein from lymphocytes
- the extraction buffer for the lysis of protoplast.
cOmplete™ is used for the inhibition of serine, cysteine, and metalloproteases in bacterial, mammalian, yeast, and plant cell extracts.
cOmplete contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete contains EDTA (1 tablet yields a 1 mM EDTA solution in 50 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography. Alternatively, the product cOmplete, EDTA-free, can be used. These tablets are identical to cOmplete, with the exception that no EDTA or other chelating agent is present.
cOmplete Tablets inhibit proteolytic activity in large extraction volumes (up to 50 ml). If you are working with smaller volumes (up to 10 ml), we recommend to use cOmplete, Mini. The composition of the cOmplete, Mini Tablet, is identical to the normal cOmplete Tablet.
cOmplete contains both reversible and irreversible protease inhibitors. Therefore, we recommend the addition of cOmplete to all stock buffers and solutions normally protected with protease inhibitors, and not just during the initial purification steps.
cOmplete contains EDTA (1 tablet yields a 1 mM EDTA solution in 50 ml). Therefore, the extraction buffer should not contain divalent cations like Ca2+, Mg2+, or Mn2+, otherwise the inhibition of the metalloproteases might be incomplete. If the protein of interest will be purified by IMAC (Immobilized Metal Affinity Chromatography), for example, Poly-His-tagged recombinant proteins, EDTA has to be eliminated (e.g., by dialysis) prior to the chromatography. Alternatively, the product cOmplete, EDTA-free, can be used. These tablets are identical to cOmplete, with the exception that no EDTA or other chelating agent is present.
cOmplete Tablets inhibit proteolytic activity in large extraction volumes (up to 50 ml). If you are working with smaller volumes (up to 10 ml), we recommend to use cOmplete, Mini. The composition of the cOmplete, Mini Tablet, is identical to the normal cOmplete Tablet.
Características y beneficios
Use cOmplete Protease Inhibitor Tablets to protect your proteins from a wide range of proteases. In just minutes, uninhibited proteolytic activity can degrade the protein you have spent days isolating. Each of these convenient water-soluble tablets contains a blend of protease inhibitors that inhibits proteolytic activity from most cell types, including animals, plants, yeast, and bacteria. No weighing or measuring is necessary, ensuring consistent results.
- Convenience: Simply push the quick-dissolving tablet through the foil packaging of the EASYpack into your buffer.
- Complete protection: Instantly protect your proteins against a broad range of proteases.
- Flexible: Protect proteins in extracts from almost any tissue or cell, including animals, plants, yeast, bacteria, or fungi.
- Safe: Choose non-toxic inhibitors that pose no risk to you or those around you.
Envase
20 individually packed cOmplete Protease Inhibitor Cocktail Tablets in foil blisters.
Componentes
Proprietary mixture of several protease inhibitors with broad inhibitory specificity.
Forma física
Tablets in foil blister packs
Nota de preparación
Working concentration: 1 tablet per 50ml extraction solution
Working solution: Handling
Carefully push the tablet through the foil packaging using the base of your thumb (not finger nail) to prevent the breakage of tablets.
Preparation of Working Solution
One cOmplete tablet is sufficient for the inhibition of the proteolytic activity in 50ml extraction solution. When a very high proteolytic activity is present, one tablet should be used for 25ml extraction buffer. Tablets can be added directly to the extraction medium. Alternatively, a stock solution (25 X conc.) can be prepared.
Preparation of Stock solution (25 X conc.)
Dissolve one cOmplete tablet in 2ml dist. water or in 2ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8°C for 1 to 2 weeks, or at least 12 weeks at -15 to -25°C.
Working solution: Handling
Carefully push the tablet through the foil packaging using the base of your thumb (not finger nail) to prevent the breakage of tablets.
Preparation of Working Solution
One cOmplete tablet is sufficient for the inhibition of the proteolytic activity in 50ml extraction solution. When a very high proteolytic activity is present, one tablet should be used for 25ml extraction buffer. Tablets can be added directly to the extraction medium. Alternatively, a stock solution (25 X conc.) can be prepared.
Preparation of Stock solution (25 X conc.)
Dissolve one cOmplete tablet in 2ml dist. water or in 2ml 100 mM phosphate buffer, pH 7.0.
Storage conditions (working solution): The stock solution can be stored at 2 to 8°C for 1 to 2 weeks, or at least 12 weeks at -15 to -25°C.
Reconstitución
Soluble in aqueous buffers, or add directly to extraction media. Alternatively, prepare 25x stock solutions in 2 ml water or 100 mM phosphate buffer, pH 7.0. Stock solution is stable for 1-2 weeks at 2 to 8 °C or at least 12 weeks at -15 to -25 °C; can be used in thiol-containing solutions at 15 to 25 °C.
Almacenamiento y estabilidad
Store at 2 to 8 °C. (storage at -15 to -25 °C is also possible)
Información legal
cOmplete is a trademark of Roche
Palabra de señalización
Danger
Frases de peligro
Clasificaciones de peligro
Eye Dam. 1 - Skin Corr. 1B
Código de clase de almacenamiento
8A - Combustible, corrosive hazardous materials
Clase de riesgo para el agua (WGK)
WGK 2
Punto de inflamabilidad (°F)
does not flash
Punto de inflamabilidad (°C)
does not flash
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
ProBDNF/p75NTR/sortilin pathway is activated in peripheral blood of patients with alcohol dependence
Zhou L, et al.
Translational Psychiatry, 7(11), 2-2 (2018)
Yuying Zhao et al.
Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society, 32(9), e13895-e13895 (2020-06-10)
Hirschsprung's disease (HSCR) is a congenital gastrointestinal disorder, characterized by enteric ganglia absence in part or entire of the colon, due to abnormal colonization and migration of enteric neural crest cells (ENCCs) during development. Currently, besides surgery which is the
Yanke Chen et al.
Nature cell biology, 22(10), 1276-1285 (2020-10-03)
Breast cancer brain metastasis (BCBM) is a devastating disease. Radiation therapy remains the mainstay for treatment of this disease. Unfortunately, its efficacy is limited by the dose that can be safely applied. One promising approach to overcoming this limitation is
The receptor-like cytoplasmic kinase BIK1 localizes to the nucleus and regulates defense hormone expression during plant innate immunity
Lal NK, et al.
Cell host & microbe, 23(4), 485-497 (2018)
Sinead Toomey et al.
Journal of translational medicine, 18(1), 99-99 (2020-02-24)
An increasing number of anti-cancer therapeutic agents target specific mutant proteins that are expressed by many different tumor types. Successful use of these therapies is dependent on the presence or absence of somatic mutations within the patient's tumor that can
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico